Intellectual Property Challenges In AI-Driven Drug Discovery
The adoption of artificial intelligence-based drug discovery platforms within the biopharmaceutical industry presents new challenges to intellectual property rights that may require reexamining existing patent doctrines....To view the full article, register now.
Already a subscriber? Click here to view full article